NEW YORK – Bio-Path Holdings has dosed the first patient in its Phase I clinical trial evaluating BP1002, a BCL-2 inhibitor, as a treatment for refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients.
The trial has enrolled six patients to evaluate BP1002 as a monotherapy. The primary endpoints are determining the safety and tolerability of escalating doses of BP1002, the recommended Phase 2 dose of BP1002, pharmacokinetics of BP1002, and BP1002 activity on BCL-2 expression. Secondary endpoints are measurements of tumor response.